Propensity score matching analysis comparing the efficacy of Ruxolitinib to historical controls in second-line or beyond treatment for chronic GvHD after steroid failure-Reference-Cited by-同舟云学术

Propensity score matching analysis comparing the efficacy of Ruxolitinib to historical controls in second-line or beyond treatment for chronic GvHD after steroid failure

Published:2023-06-26 Issue:9 Volume:58 Page:1024-1032
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Novitzky-Basso Igor^ORCID,Linn Swe Mar,White Jennifer,Elemary Mohamed,Xenocostas Anargyros,Deotare Uday^ORCID,Kelly Kate,Hamad Nada^ORCID,Tan Sui,Culos Samantha,Law Arjun^ORCID,Kumar Rajat^ORCID,Mattsson Jonas,Kim Dennis Dong Hwan

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-02020-5.pdf

Reference21 articles.

1. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23:211–34. https://doi.org/10.1016/j.bbmt.2016.09.023.

2. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33. https://doi.org/10.1053/bbmt.2003.50026.

3. Cho BS, Lee SE, Song HH, Lee JH, Yahng SA, Eom KS, et al. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes. Biol Blood Marrow Transplant. 2012;18:1136–43. https://doi.org/10.1016/j.bbmt.2012.01.010.

4. Saillard C, Crocchiolo R, Furst S, El-Cheikh J, Castagna L, Signori A, et al. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leuk Lymphoma. 2014;55:1106–12. https://doi.org/10.3109/10428194.2013.820285.

5. Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021;385:228–38. https://doi.org/10.1056/NEJMoa2033122.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease;Journal of Clinical Medicine;2024-07-22

2. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development;Current Oncology;2024-03-08

3. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation;The Lancet Haematology;2024-02